THERMO FISHER SCIENTIFIC INC.

NYSE: TMO·Waltham, Massachusetts·

Price
$691.33
Base IV
$204.80

Valuation snapshot

Above bull case

At $691.33, the price is above even our bull case of $282.14.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$204.80
30% of the price · range $139.72–$282.14
Price vs base case
238% above
$691.33 against $204.80
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $139.72 to bull $282.14. Values per share.

Price against each value

Bear case
$139.72
Price 395% above
No growth
…
—
Base case
$204.80
Price 238% above
Researched bygemini-3.8-flash-medium
Valuation Oct 31, 2026 · Price as of Nov 16, 2026How we got here

What does Thermo Fisher Scientific do?

Thermo Fisher Scientific provides laboratory instruments, reagents, and consumables to help pharmaceutical, biotech, and research customers conduct biological research, develop drugs, and perform clinical diagnostics.

It brought in $47.4B of sales in the 12 months to Sep 2026.

Applied Biosystems QuantStudio 5 real-time PCR systemAjay Kumar Chaurasiya, CC BY-SA 4.0, via Wikimedia Commons
Industry
Semiconductors
Based in
Waltham, Massachusetts
Trades on
NYSE as TMO

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 15¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 60¢ of every dollar.

  • Research and development3¢
  • Sales, marketing and admin19¢
  • Everything else it takes to operate60¢
  • Interest and other costs1¢
  • Tax2¢
  • Left as profit15¢
Totals of the four quarters to Sep 2026, from the company's own filings.

Who pays Thermo Fisher Scientific, and for what?

Thermo Fisher sells the tools, chemicals, lab supplies, instruments and diagnostic tests that scientists and labs use every day. It also earns fees by running drug development, clinical trials and drug manufacturing for drug companies. A large share of sales comes from repeat purchases of supplies and services.

Mostly businesses and institutions: drug and biotech companies, hospitals and diagnostic labs, universities, research institutes, government agencies, and industrial and environmental labs.

  • Laboratory Products and Biopharma Services

    Lab equipment, chemicals and supplies, a distribution channel for research and safety products, plus outsourced drug manufacturing and clinical trial services for drug companies. Its largest line; revenue grew 4% in 2025. Segment shares add up to slightly more than 100% because sales between segments are removed from the company total.

  • Life Sciences Solutions

    Reagents, instruments and supplies for biological research, genetic analysis and the production of biologic drugs and vaccines. Revenue grew 8% in 2025, led by its bioproduction business and helped by buying Solventum's filtration business.

    Applied Biosystems QuantStudio 5 real-time PCR systemAjay Kumar Chaurasiya, CC BY-SA 4.0, via Wikimedia Commons
  • Analytical Instruments

    Instruments that measure and identify substances, such as mass spectrometers and electron microscopes, plus the software, supplies and service that go with them. Customers include research, industrial, semiconductor and environmental labs. Revenue grew 1% in 2025.

    Thermo Scientific Krios 5 cryo-electron microscopeImage: Sensu
  • Specialty Diagnostics

    Diagnostic test kits, reagents and instruments for hospitals and clinical labs, covering allergy, autoimmune disease, drug monitoring, transplant matching and microbiology. Revenue grew 4% in 2025. The company announced in 2026 that it is selling the microbiology business.

We don't have each line's share of sales for this company yet.

Where its work physically happens, beyond headquarters:

  • Greenville Pharma Services Site — Greenville, United States. Thermo Fisher identifies Greenville as its largest manufacturing site, providing high-volume sterile fill-finish, prefilled-syringe and commercial packaging capacity for pharmaceutical and biologic products.
  • Lengnau Biologics Manufacturing Site — Lengnau, Switzerland. The 1.5-million-square-foot site provides flexible single-use and stainless-steel biologics production with bioreactor capacity up to 12,500 liters, enabling development through large-scale commercial supply.
  • Grand Island Cell Culture Media Facility — Grand Island, United States. This 307,034-square-foot facility manufactures cell-culture media, reagents and sera, with a 45,000-square-foot expansion that doubled capacity for granulated media used in vaccine and biologics production.
  • Plainville Viral Vector Manufacturing Site — Plainville, United States. The $180 million, 290,000-square-foot facility more than doubled Thermo Fisher's commercial viral-vector capacity for gene therapies and vaccines.
  • St. Louis Biologics Center of Excellence — St. Louis, United States. This center provides process development and clinical and commercial cGMP biologics manufacturing, with an expansion that doubled capacity and created one of the CDMO industry's largest single-use bioproduction footprints.
See them on the globe

Thermo Fisher Scientific 10-K for fiscal 2025

How is the business doing?

Sales grew from $32.2B in 2020 to $44.6B in 2025, about 7% a year.

Running the business leaves about 18¢ of each sales dollar as operating profit, down from 24¢ in 2020.

After paying for its upkeep and new investment, it had $7.6B of cash to spare in the 12 months to Sep 2026.

Sales$44.6B
20162025
Operating margin17%
20162025
Free cash flow$6.3B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Thermo Fisher says it exists to help its customers, mostly scientists, labs and drug makers, make the world healthier, cleaner and safer.

“Our Mission is to enable our customers to make the world healthier, cleaner and safer.”

Thermo Fisher Scientific 10-K for fiscal 2025

What management says it is working on now:

  • Three-part growth strategy

    Management says its growth plan rests on three things: new products that make a real difference, being a trusted partner to customers, and a large sales and distribution network that can sell many products to the same customers.

    Thermo Fisher Scientific 10-K for fiscal 2025
  • Cutting costs and improving efficiency

    The company's in-house improvement program, which covers pricing, sourcing, closing facilities and cutting jobs, lifted profit margins in 2025. Management expects the 2025 restructuring to save about $0.5 billion a year.

    Thermo Fisher Scientific 10-K for fiscal 2025
  • Growing through acquisitions

    The company says acquisitions are its main use of cash. It bought Solventum's filtration business in 2025 and agreed to buy Clario, a clinical trial data company, for about $8.9 billion. Clario joins the lab products and drug services segment.

    Thermo Fisher Scientific 10-K for fiscal 2025
  • Returning cash to shareholders

    After acquisitions, the company uses cash for share buybacks and dividends. On its second-quarter 2026 call it said it plans about $4 billion of buybacks and about $700 million of dividends in 2026.

    Thermo Fisher Q2 2026 earnings call transcript
  • Investing in research, capacity and AI

    The company keeps spending heavily on research and new products and is building AI into its products and internal processes. It expects to spend $1.8 billion to $2.0 billion on buildings and equipment in 2026.

    Thermo Fisher Scientific 10-K for fiscal 2025
Revenue, Full year 2026 (raised July 2026)
$47.4 billion to $48.1 billion (about 6% to 8% above 2025)
Thermo Fisher Q2 2026 earnings call transcript
Adjusted earnings per share, Full year 2026 (raised July 2026)
$24.93 to $25.33
Thermo Fisher Q2 2026 earnings call transcript
Free cash flow, Full year 2026
$6.9 billion to $7.4 billion
Thermo Fisher Q2 2026 earnings call transcript
Organic revenue growth (growth excluding acquisitions and currency effects), Long term (2026 Investor Day)
7% a year
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Adjusted earnings per share growth, Long term (2026 Investor Day)
Low teens percent a year
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Adjusted tax rate, Full year 2026
About 11.5% (reported tax rate 7% to 9%)
Thermo Fisher Scientific 10-K for fiscal 2025
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 9% more than a year earlier. The year before, quarters averaged 7%.

Its operating margin is wider than a year ago: 19¢ per sales dollar, against 17¢.

Since Sep 2026 the share price has risen 12%, from $618.43 to $691.33.

Bull $282.14Base $204.80Bear $139.72Sep 4Nov 16 · $691.33
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start September 4, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $149.01 to $204.80 a share between our last two valuations. The biggest reason: Purchases of Property, Plant, and Equipment, Full Year moved from an unreported prior value to $1.5B, as reported in Thermo Fisher Scientific 2025 Form 10-K.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Research budgets and China

    Sales to universities and government labs fell in 2025 because U.S. customers held back during policy uncertainty, and sales in China declined. Budget cuts, delayed funding or government shutdowns could reduce what these customers buy.

    From the company's own filingsWould hit how fast sales growThermo Fisher Scientific 10-K for fiscal 2025

  2. Tariffs and global trade

    The company makes and sells products in many countries, so tariffs, trade restrictions and currency swings affect it. Tariffs were a main reason the Analytical Instruments segment's profit margin fell from 26.2% to 23.0% in 2025.

    From the company's own filingsWould hit how much of each sale it keepsThermo Fisher Scientific 10-K for fiscal 2025

  3. Acquisitions and higher debt

    Large purchases may not work out as planned. Total debt rose from $31.3 billion to $39.4 billion in 2025. The company warns that the value of the newly bought filtration business is only slightly above what it paid, so a write-down is possible if results disappoint.

    From the company's own filingsWould hit how much it has to reinvestThermo Fisher Scientific 10-K for fiscal 2025

  4. Quality problems in drug manufacturing

    Making drugs for other companies is demanding and closely inspected. A quality failure could mean destroyed batches, shut-down plants, recalls, regulator penalties or claims from customers for expensive lost ingredients.

    From the company's own filingsWould hit how much of each sale it keepsThermo Fisher Scientific 10-K for fiscal 2025

  5. Drug pricing and health rules

    Changes such as U.S. drug price negotiation under the Inflation Reduction Act, or new FDA rules, could lead drug companies to spend less on research and manufacturing, which would lower demand for Thermo Fisher's products and services.

    From the company's own filingsWould hit how fast sales growThermo Fisher Scientific 10-K for fiscal 2025

  6. Keeping up with technology and rivals

    The company faces strong competition almost everywhere it sells. If competitors, including some of its own large customers and suppliers, adopt new technology such as AI faster, its products could fall behind and sales could suffer.

    From the company's own filingsWould hit how fast sales growThermo Fisher Scientific 10-K for fiscal 2025

  7. Year-over-year revenue was essentially flat at 0.05% in 2024 and grew only 3.9% in 2025, highlighting risks of prolonged macro digestion periods.

    From our researchWould hit how fast sales growThermo Fisher Scientific 2025 Form 10-K

  8. Large transformational acquisitions periodically elevate total capital deployment well above routine operational cash reinvestment.

    From our researchWould hit how much it has to reinvestThermo Fisher Scientific PPD Acquisition Completion Disclosures

Is it a good business?

From 2016 to 2025 it earned between 6% and 15% on the capital invested in it, a median of 9%. Its cost of capital in the latest valuation is 8.3%; returns were above it in 7 of the 10 years.

From 2016 to 2025 it earned between 9% and 19% on its shareholders' equity, a median of 13%.

Over 10 years its operating margin ranged from 13¢ to 26¢ per sales dollar, a median of 17¢. Gross margin ran from 44¢ to 46¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital8%
20162025

Cost of capital 8.3%

Return on equity13%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 9%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

It bought back shares: the count fell 1.9% in a year, so each remaining share owns a slightly bigger slice.

It owes $35.9B more than it holds in cash, about 4.2 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $691.33. Our put its value between $139.72 and $282.14, with $204.80 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $139.72

This scenario envisions a muted recovery where the recent rebound in laboratory equipment orders fades into persistent customer budget constraints and sluggish biotech activity, keeping sales and profit gains well below historic norms.

Base case, $204.80

This scenario envisions steady continuation of the post-2024 recovery, where demand for clinical trial services and analytical instruments stabilizes to deliver healthy, durable earnings expansion.

Bull case, $282.14

This scenario envisions an accelerating expansion building on the recent high-single-digit sales momentum, powered by a full resurgence in pharmaceutical clinical trials, strong manufacturing demand, and expanding profitability.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 238%

For Thermo Fisher Scientific to be worth today's $691.33, sales would need to grow about 29.9% a year. We assume 5.6%. Over the last 5 years, sales grew 3.9% a year.

−10%0%+10%+20%+30%+40%Past 5 yrs 3.9%We assume 5.6%Price needs 29.9%

Or, if sales grow 5.6% as we assume, the price works with a profit margin of 48.3% (we assume 18.5%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 29.9% a year?

Try your own numbers

We're moderately sure of this range: it scores 70 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $204.80 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average5.6%
  • Operating margin18.5%
  • Long-term growth rate2.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$204.80 -70.4%

Build